Zhejiang Carbiogene Therapeutics Co., Ltd. (Carbiogene) is a “5050 Plan” company introduced by the Hangzhou National High-Tech Zone, and a National High-Tech Enterprise supported by government funding. Carbiogene is an innovative biotechnology company co-founded by renowned scientists from China and abroad, integrating R&D, production, and sales. Its core team is composed of internationally influential medical scientists.

Carbiogene's R&D and manufacturing center is built according to AABB standards, with a standard GMP clean workshop and world-class laboratory equipment. It has passed ISO certification for three management systems, establishing a closed-loop industry led by new anti-tumor immunotherapy products, including new-generation CAR-T and CAR-NK therapies, and supported by tumor DC vaccines, immune cells, stem-cell biological resources, molecular tumor diagnostics, laboratory testing, and medical health big data. Following the company philosophy, “cure sickness to save patients,” Carbiogene introduces the world's leading precision tumor immunotherapy technology platform and promotes the clinical translation of next-generation precision tumor immunotherapy, creating a globally influential and innovative biotechnology company.

Since its establishment, the company has developed steadily and achieved gratifying results. It has been recognized as a National High-Tech Enterprise, a participant in the Zhejiang Provincial Key R&D Program, a Zhejiang High-Tech Enterprise R&D Center, a Hangzhou Expert Workstation, a Zhejiang High-Growth Technology Enterprise, and an Overseas High-Level Talent Innovation and Entrepreneurship Enterprise. It has also received funding support from numerous provincial and municipal key projects. The company has independently developed more than 100 invention patents, utility model patents, and software copyrights, and has passed certification under the Enterprise Intellectual Property Management System.